Our approach is to interface tissue engineering with microtechnologies, such as microfluidics and microarrays, to incorporate biological complexity into quantitative screening platforms. Through this effort, we expect to capture more complex multi-cellular phenotypes and interactions to bridge between simplistic single cell-based assays and animal studies.